Insider Selling: Liquidia (NASDAQ:LQDA) CEO Sells 25,000 Shares of Stock

Key Points

• Roger Jeffs, Liquidia's CEO, sold 25,000 shares on May 5 at an average price of $40.10 for $1,002,500, leaving him with 1,398,095 shares (a 1.76% reduction); the sale was executed under a Rule 10b5-1 plan.
• The May 5 trade is part of a series of recent disposals — including 25,000 shares on May 7 at $42.09 and multiple April sales (several ~25,000-share lots and other amounts) — representing repeated monetizations each worth roughly $100k–$1.3M.
• Liquidia shares trade near $42.28 with a 1-year range of $11.85–$46.67 and a $3.76 billion market cap; analysts hold a consensus "Moderate Buy" with a $43.44 target after the company posted a revenue beat and $0.15 EPS despite negative margins and ROE.

Liquidia Corporation (NASDAQ:LQDA - Get Free Report) CEO Roger Jeffs sold 25,000 shares of the business's stock in a transaction on Tuesday, May 5th. The stock was sold at an average price of $40.10, for a total value of $1,002,500.00. Following the transaction, the chief executive officer directly owned 1,398,095 shares of the company's stock, valued at $56,063,609.50. This trade represents a 1.76% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Roger Jeffs also recently made the following trade(s):

• On Thursday, May 7th, Roger Jeffs sold 25,000 shares of Liquidia stock. The stock was sold at an average price of $42.09, for a total value of $1,052,250.00.
• On Friday, April 17th, Roger Jeffs sold 18,839 shares of Liquidia stock. The stock was sold at an average price of $40.60, for a total value of $764,863.40.
• On Wednesday, April 15th, Roger Jeffs sold 25,000 shares of Liquidia stock. The stock was sold at an average price of $40.14, for a total value of $1,003,500.00.
• On Tuesday, April 14th, Roger Jeffs sold 3,300 shares of Liquidia stock. The stock was sold at an average price of $40.00, for a total value of $132,000.00.
• On Monday, April 13th, Roger Jeffs sold 32,744 shares of Liquidia stock. The stock was sold at an average price of $38.37, for a total value of $1,256,387.28.
• On Friday, April 10th, Roger Jeffs sold 21,433 shares of Liquidia stock. The stock was sold at an average price of $40.12, for a total value of $859,891.96.
• On Thursday, April 9th, Roger Jeffs sold 25,000 shares of Liquidia stock. The stock was sold at an average price of $40.12, for a total value of $1,003,000.00.

Liquidia Price Performance

Shares of Liquidia stock traded up $0.14 during trading on Thursday, reaching $42.28. 1,196,501 shares of the company's stock were exchanged, compared to its average volume of 1,625,170. The company has a debt-to-equity ratio of 2.97, a quick ratio of 1.84 and a current ratio of 2.01. Liquidia Corporation has a 1-year low of $11.85 and a 1-year high of $46.67. The company has a market cap of $3.76 billion, a P/E ratio of -50.94 and a beta of 0.41. The firm's 50-day moving average price is $36.79 and its 200 day moving average price is $34.57.

Liquidia (NASDAQ:LQDA - Get Free Report) last issued its earnings results on Thursday, March 5th. The company reported $0.15 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.08 by $0.07. Liquidia had a negative return on equity of 209.33% and a negative net margin of 43.53%.The business had revenue of $92.02 million during the quarter, compared to analysts' expectations of $87.49 million. The business's revenue was up 3072.4% on a year-over-year basis. As a group, research analysts anticipate that Liquidia Corporation will post 1.75 earnings per share for the current year.

Institutional Investors Weigh In On Liquidia

Institutional investors and hedge funds have recently made changes to their positions in the stock. Federated Hermes Inc. acquired a new stake in shares of Liquidia in the third quarter valued at about $7,290,000. Caprock Group LLC bought a new stake in shares of Liquidia during the 3rd quarter valued at about $37,114,000. Farallon Capital Management LLC boosted its position in shares of Liquidia by 102.1% during the 3rd quarter. Farallon Capital Management LLC now owns 8,565,638 shares of the company's stock valued at $194,783,000 after purchasing an additional 4,326,876 shares in the last quarter. Apis Capital Advisors LLC bought a new stake in shares of Liquidia during the 3rd quarter valued at about $9,569,000. Finally, Campbell & CO Investment Adviser LLC bought a new stake in shares of Liquidia during the 3rd quarter valued at about $2,026,000. Institutional investors and hedge funds own 64.54% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on LQDA shares. Zacks Research raised Liquidia from a "hold" rating to a "strong-buy" rating in a report on Tuesday. Wells Fargo & Company upped their target price on Liquidia from $44.00 to $51.00 and gave the stock an "overweight" rating in a report on Monday, March 23rd. Oppenheimer upped their target price on Liquidia from $16.00 to $19.00 and gave the stock an "underperform" rating in a report on Thursday, March 12th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Liquidia in a report on Tuesday, April 21st. Finally, Lifesci Capital raised Liquidia to a "strong-buy" rating in a report on Thursday, March 5th. Three investment analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, Liquidia currently has a consensus rating of "Moderate Buy" and a consensus price target of $43.44.

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company's lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.